Are the current preclinical models adequate to evaluate CAR-T cell therapy in pediatric high-grade gliomas?
Molecular Therapy · 2026
DOI: 10.1016/j.ymthe.2026.06.043 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Therapy, 2026. Verfasst von Ana Muñoz Grau und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Technology and Biopharmacy, Groningen Research Institute of Pharmacy, University of Groningen, AV Groningen 9713, the Ne…. Hauptthemen laut MEDLINE: Glioma, Immunotherapy, Adoptive, Receptors, Chimeric Antigen, Brain Neoplasms. Die Arbeit nennt 115 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Rijksuniversiteit Groningen.
Abstract (Originalsprache)
Pediatric high-grade gliomas (pHGGs) are aggressive childhood brain tumors with 5-year survival rates below 20%. They are distinct from adult HGGs (aHGGs) and are driven by histone mutations, disrupted developmental programs, and an immunologically restrained tumor microenvironment (TME). While chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment of hematological malignancies, its application to pHGGs faces significant challenges for clinical translation. This perspective aims to provide a comprehensive overview of pHGG biology, CAR-T cell therapy principles, and current preclinical models, highlighting translational gaps and strategies to bridge them. We first examined the molecular and cellular landscape of pHGGs, emphasizing the unique features that shape responsiveness to antigen-directed therapies, detailing the mechanisms of CAR-T therapy, successes in hematological malignancies, and specific challenges in central nervous system (CNS) tumors. Next, we critically discussed the preclinical platforms, ranging from traditional 2D cultures to advanced patient-derived 3D systems and in vivo mouse models. While these systems provide mechanistic insights and enable assessment of CAR-T efficacy, none fully replicate the pediatric TME or developmental context, contributing to the recurrent gap between preclinical efficacy and clinical outcomes. This perspective highlights current knowledge, translational limitations, and future strategies to enhance CAR-T research in pediatric neuro-oncology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Technology and Biopharmacy, Groningen Research Institute of Pharmacy, University of Groningen, AV Groningen 9713, the Netherlands.
- Centre for Discovery in Cancer Research, McMaster University, Hamilton, ON L8S 4L8, Canada; Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON L8S 4L8, Canada.
- Centre for Discovery in Cancer Research, McMaster University, Hamilton, ON L8S 4L8, Canada; Department of Surgery, McMaster University, Hamilton, ON L8S 4L8, Canada.
- Centre for Discovery in Cancer Research, McMaster University, Hamilton, ON L8S 4L8, Canada; Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON L8S 4L8, Canada; Department of Surgery, M…
- Department of Pharmaceutical Technology and Biopharmacy, Groningen Research Institute of Pharmacy, University of Groningen, AV Groningen 9713, the Netherlands. Electronic address: flavia.sousa@rug.nl.
Förderung
- Rijksuniversiteit Groningen
Zitieren
APA
Grau, A. M., Hameedat, F., Hussein Sokeechand, B. S., Venugopal, C., Singh, S., & Sousa, F. (2026). Are the current preclinical models adequate to evaluate CAR-T cell therapy in pediatric high-grade gliomas?. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2026.06.043
Vancouver
Grau AM, Hameedat F, Hussein Sokeechand BS, Venugopal C, Singh S, Sousa F. Are the current preclinical models adequate to evaluate CAR-T cell therapy in pediatric high-grade gliomas?. Molecular Therapy. 2026. doi:10.1016/j.ymthe.2026.06.043
BibTeX
@article{Grau2026,
author = {Grau, Ana Muñoz and Hameedat, Fatima and Hussein Sokeechand, Bibi Sumayyah and Venugopal, Chitra and Singh, Sheila and Sousa, Flávia},
title = {Are the current preclinical models adequate to evaluate CAR-T cell therapy in pediatric high-grade gliomas?},
journal = {Molecular Therapy},
year = {2026},
doi = {10.1016/j.ymthe.2026.06.043}
}
EUVIMED